December 4, 2019
Wired reporter Megan Molteni writes that MIT researchers have developed a slow-release pill that can gradually deliver one month’s worth of contraceptive drugs. “From an engineering aspect, the key novelty is the ability to deliver a drug for a month after a single ingestion event,” explains Prof. Giovanni Traverso.
Prof. Asu Ozdaglar, head of EECS, speaks with John Thornhill of the Financial Times about the Schwarzman College of Computing and the complex challenges posed by new technologies. “The excitement around how these technologies can transform society is very real,” says Ozdaglar. “But we should also be aware of their possible negative consequences.”
Prof. Kate Brown speaks with Rachel Toor of The Chronicle of Higher Education about writing, delving into why she writes in the first person and her interest in “genre-busting” history. “Thinking about writing in the first person has inspired me to get up from my desk and out of the archive to explore the landscapes and communities that are the settings of my histories,” Brown explains.
WGBH’s Jared Bowen spotlights the MIT Museum’s exhibit exploring the history of Polaroid photography in a special segment for the PBS NewsHour. “It was a very small thing you could hold in the hand, but you had to participate in the making of the picture,” says William Ewing, one of the exhibit’s curators.
Alexander Agadjanian, a senior research support associate at the MIT Election Data and Science Lab, writes for The New York Times about how he and his colleagues developed a Twitter account that showcases the complexities of individual voters’ stances on issues. Agadjanian explains that the account displays “American voters, and nonvoters, remain complex as a whole.”
Boston Globe Jonathan Saltzman writes that a study by researchers from the Broad Institute of MIT and Harvard finds that drugs developed for diabetes, inflammation and alcoholism could be used to combat cancer cells in the lab. “The results could suggest ways to speed the development of new cancer drugs or repurpose existing drugs to treat cancer,” writes Saltzman.